#Sweden #Stockholm #Endometriosis #Gesynta Pharma #vipoglanstat

Gesynta Pharma Takes a Crucial Step in Endometriosis Treatment

Gesynta Pharma AB has announced a pivotal advancement in the assessment of vipoglanstat, a promising candidate for treating endometriosis. On March 11, 2026, the company revealed that the first patient has been dosed in their Phase 2 clinical proof-of-concept trial, known as the NOVA trial. This significant milestone marks a move towards developing a much-needed therapeutic option for approximately 190 million women globally who suffer from this painful chronic condition.

Endometriosis, characterized by the growth of endometrium-like tissue outside the uterus, leads to chronic inflammation, debilitating pain, and infertility. As many as 10% of women of reproductive age are affected, yet the condition remains largely underdiagnosed and overlooked. Current treatment options are limited and often ineffective, highlighting the urgent need for fresh approaches like vipoglanstat.

The NOVA trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two different doses of vipoglanstat in comparison to a placebo. Over the course of the trial, approximately 190 women, aged between 18 and 45, will be enrolled from various countries including the UK, Italy, Poland, Romania, Bulgaria, the Czech Republic, and Hungary. Participants will receive either the vipoglanstat or a placebo orally for four menstrual cycles, during which the primary objective will be to assess the drug’s impact on pain associated with endometriosis on non-menstrual days. Secondary endpoints include evaluating its effects on dysmenorrhea (period pain), dyspareunia (pain during sexual intercourse), the usage of opioid medications, and various quality-of-life assessments. Additional exploratory assessments will review endometriotic lesions via MRI. The results of this trial are anticipated to be unveiled in 2027.

Christian Becker, the Professor of Reproductive Sciences and Co-Director of the Oxford Endometriosis CaRe Centre, expressed optimism regarding this trial. He emphasized the importance of expanding treatment options for women who face persistent pain and reduced functionality despite the existing therapies. "I am excited to work with Gesynta to assess whether vipoglanstat can deliver meaningful, lasting improvements for patients," he stated.

The mechanism of action for vipoglanstat centers around targeting mPGES-1, an enzyme that produces prostaglandin E2 (PGE2), a potent proinflammatory mediator found in endometriotic lesions. Previous preclinical studies indicated that vipoglanstat markedly reduced both pain-associated behaviors and the load of endometriotic lesions in advanced models of the disease. Additionally, its safety and tolerability were confirmed in prior clinical trials, thus providing strong support for the ongoing development of vipoglanstat as a viable treatment option for endometriosis.

Patric Stenberg, CEO of Gesynta Pharma, remarked on the importance of the first patient dosing in the NOVA trial, recognizing it as a crucial milestone in the development of vipoglanstat. Stenberg communicated that the focus of this trial is to generate robust, controlled data regarding pain relief and overall quality of life for women suffering from moderate to severe endometriosis.

As the NOVA trial progresses, it brings a glimmer of hope not only for women battling endometriosis but also for the medical community striving for effective solution. The study aims to address the significant barriers faced in current treatment landscapes and potentially reshape the future of endometriosis management with vipoglanstat.

About Gesynta Pharma

Gesynta Pharma began its research targeting mPGES-1 in Sweden at the Karolinska Institutet. The company is dedicated to developing innovative treatments for chronic inflammatory conditions, with vipoglanstat as its leading compound in the fight against endometriosis. As additional developments progress, Gesynta continues to focus on improving the lives of women affected by this challenging condition and aims for a comprehensive approach to tackle the unmet medical needs in this domain. For more details, visit Gesynta Pharma's website.